Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Cytori Therapeutics (CYTX) Competitors

Cytori Therapeutics logo

CYTX vs. CRIS, SABS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIB

Should you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include Curis (CRIS), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry.

Cytori Therapeutics vs.

Cytori Therapeutics (NASDAQ:CYTX) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.

Curis has a consensus target price of $17.00, indicating a potential upside of 750.00%. Given Curis' stronger consensus rating and higher possible upside, analysts clearly believe Curis is more favorable than Cytori Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytori Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Curis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cytori Therapeutics has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.65, suggesting that its stock price is 265% more volatile than the S&P 500.

Cytori Therapeutics has a net margin of -242.60% compared to Curis' net margin of -443.35%. Cytori Therapeutics' return on equity of -272.70% beat Curis' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytori Therapeutics-242.60% -272.70% -56.23%
Curis -443.35%-923.37%-78.35%

Cytori Therapeutics has higher earnings, but lower revenue than Curis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytori Therapeutics$3.67M1.89-$12.63MN/AN/A
Curis$11.20M1.87-$47.41M-$6.23-0.32

2.6% of Cytori Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 0.7% of Cytori Therapeutics shares are held by insiders. Comparatively, 5.7% of Curis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Curis received 253 more outperform votes than Cytori Therapeutics when rated by MarketBeat users. However, 73.67% of users gave Cytori Therapeutics an outperform vote while only 67.28% of users gave Curis an outperform vote.

CompanyUnderperformOutperform
Cytori TherapeuticsOutperform Votes
442
73.67%
Underperform Votes
158
26.33%
CurisOutperform Votes
695
67.28%
Underperform Votes
338
32.72%

In the previous week, Curis had 6 more articles in the media than Cytori Therapeutics. MarketBeat recorded 6 mentions for Curis and 0 mentions for Cytori Therapeutics. Curis' average media sentiment score of 0.62 beat Cytori Therapeutics' score of 0.00 indicating that Curis is being referred to more favorably in the news media.

Company Overall Sentiment
Cytori Therapeutics Neutral
Curis Positive

Summary

Curis beats Cytori Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Cytori Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYTX vs. The Competition

MetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$6.94M$4.38B$5.33B$8.31B
Dividend YieldN/A43.63%5.20%4.10%
P/E RatioN/A29.0626.7219.60
Price / Sales1.8973.00395.56117.92
Price / CashN/A51.0838.3234.62
Price / Book0.896.186.764.50
Net Income-$12.63M$66.96M$3.23B$248.40M

Cytori Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYTX
Cytori Therapeutics
N/A$0.31
-7.7%
N/A-84.1%$6.94M$3.67M0.0037Gap Down
High Trading Volume
CRIS
Curis
3.054 of 5 stars
$2.12
+1.9%
$17.00
+701.9%
-81.6%$22.18M$11.20M-0.2760Analyst Revision
SABS
SAB Biotherapeutics
2.854 of 5 stars
$1.84
+2.4%
$12.20
+562.1%
-32.9%$17.12M$2.24M-0.50140
BOLT
Bolt Biotherapeutics
3.2477 of 5 stars
$0.33
+0.6%
$2.50
+658.3%
-57.5%$12.64M$7.69M-0.1990Analyst Forecast
Gap Down
MTEM
Molecular Templates
N/AN/AN/AN/A$1,000.00$23.48M0.00260
AMGN
Amgen
4.3664 of 5 stars
$275.01
-0.3%
$309.22
+12.4%
-12.1%$147.87B$34.13B36.4325,200Positive News
Analyst Forecast
Analyst Revision
GILD
Gilead Sciences
4.6331 of 5 stars
$109.11
+2.8%
$110.55
+1.3%
+57.4%$135.73B$28.74B294.8917,000Positive News
Analyst Forecast
Insider Trade
Options Volume
VRTX
Vertex Pharmaceuticals
4.6064 of 5 stars
$447.18
+1.5%
$515.04
+15.2%
-3.0%$114.83B$11.10B-203.264,800Positive News
REGN
Regeneron Pharmaceuticals
4.7857 of 5 stars
$614.79
+3.2%
$890.60
+44.9%
-39.3%$66.38B$14.09B16.0611,900Positive News
Dividend Announcement
Ex-Dividend
ALNY
Alnylam Pharmaceuticals
4.1663 of 5 stars
$291.68
-0.1%
$319.17
+9.4%
+91.5%$38.03B$2.35B-134.412,000Positive News
BIIB
Biogen
4.8959 of 5 stars
$130.55
+0.9%
$191.30
+46.5%
-43.9%$19.13B$9.82B11.678,720Positive News

Related Companies and Tools


This page (NASDAQ:CYTX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners